SCHEMBL2353383

SCHEMBL2353383

CC=C(C)[C](C)[SiH3]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25388030 0.71
SCHEMBL1350357 0.71
SCHEMBL18433299 0.71
SCHEMBL961393 0.71
SCHEMBL1277245 0.67
SCHEMBL2960262 0.64
Hydrochloric Acid SCHEMBL28334923 0.64
SCHEMBL17873990 0.64
SCHEMBL2960259 0.64
SCHEMBL6909509 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104114171-A Treatment of autoimmune disorders using RXR agonists IO THERAPEUTICS INC 2014-10-22 CN claimed
CN-101316583-A Treatment of cancer with specific rxr agonists VITAE PHARMACEUTICALS INC (US) 2008-12-03 CN claimed
CN-1121379-C Synthesis and use of retinoid having negative hormone and/or antagonist activity ALLERGAN CO (US) 2003-09-17 CN claimed
CN-1368975-A Organosilyl compounds having nuclear hormone receptor modulating activity ALLERGAN SALES INC (US) 2002-09-11 CN claimed
CN-1360890-A Use of active retiene derivative with negative hormone and/or antagonist ALLERGAN INC (US) 2002-07-31 CN claimed
CN-1211180-A Method of treatment with compounds having RAG 'alpha' receptor specific or selective activity ALLERGAN CO (US) 1999-03-17 CN claimed
CN-1209802-A Synthesis and use of retinoid having negative hormone and/or antagonist activity ALLERGAN CO (US) 1999-03-03 CN claimed
CN-1207727-A Substd. aryl or heteroarylamides having retinoid-like biological activity VISION PHARM LP (US) 1999-02-10 CN claimed
CN-1056878-A 2-substituted alkyl-3-carboxycarbapenems as antibiotics and process for their preparation AMERICAN CYANAMID CO (US) 1991-12-11 CN claimed
CN-110151745-A Use the treatment of the autoimmune disorder of rxr agonist IO治疗公司 2019-08-23 CN disclosed
CN-107861336-A Red hardening resin composition, the colour filter formed by red hardening resin composition, the display device comprising colour filter 东友精细化工有限公司 2018-03-30 CN disclosed
CN-107643653-A Cyan hardening resin composition, colour filter and display device 东友精细化工有限公司 2018-01-30 CN disclosed
CN-107004899-A It is used as the ring-type phosphonic amide of the electrolyte component of lithium ion battery 瓦克化学股份公司 2017-08-01 CN disclosed
CN-104114171-A Treatment of autoimmune disorders using RXR agonists IO THERAPEUTICS INC 2014-10-22 CN disclosed
CN-1211180-A Method of treatment with compounds having RAG 'alpha' receptor specific or selective activity ALLERGAN CO (US) 1999-03-17 CN disclosed
CN-1209802-A Synthesis and use of retinoid having negative hormone and/or antagonist activity ALLERGAN CO (US) 1999-03-03 CN disclosed
CN-1207727-A Substd. aryl or heteroarylamides having retinoid-like biological activity VISION PHARM LP (US) 1999-02-10 CN disclosed
CN-1108648-A Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them AMERICAN CYANAMID CO (US) 1995-09-20 CN disclosed
CN-1108649-A Noel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them AMERICAN CYANAMID CO (US) 1995-09-20 CN disclosed
CN-1056878-A 2-substituted alkyl-3-carboxycarbapenems as antibiotics and process for their preparation AMERICAN CYANAMID CO (US) 1991-12-11 CN disclosed